Background Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal
antibody, was efficacious in psoriasis. Objective We sought to assess efficacy and safety of …

Despite the large number of biologics currently available for moderate-to-severe psoriasis,
poor adherence and persistence to therapy represent the main issues for both the clinical …

Drug survival studies have been utilized to evaluate the real-world effectiveness of biologics
used in psoriasis. However, the increasing volume of drug survival data suffers from large …

Importance Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to
psoriatic inflammation. Objective To evaluate the efficacy and safety of risankizumab vs …

Drug survival of biologics represents their real-world effectiveness and safety. We conducted
a meta-analysis of real-world evidence on the drug survival of biologics in treating psoriasis …

Objective To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis
factor (TNF) inhibitor is associated with an increased risk of serious infection among real …

SARS‐CoV‐2 become pandemics and there is still a dearth of data about its the potentially
among dermatological patients under biologics. We aimed to assess health literacy, disease …

Background Significant advances have been made in the treatment of moderate‐to‐severe
plaque psoriasis with biological therapies; however, these agents may not work equally in …

Background Total work productivity loss (WPL) and associated indirect costs contribute to
the economic burden of psoriasis. Objectives To estimate total WPL and related indirect …

Background Switching therapies is common for patients with psoriasis. Objective To quantify
real-world switching rates and characteristics among patients initiating biologics over 24 …